NEW YORK (GenomeWeb News) — The Erasmus Medical Center will use Illumina’s BeadChips in a 10,000-subject study aimed at identifying early environmental and genetic causes of abnormal growth in fetal development, Illumina said today.
The Rotterdam, Netherlands-based research hospital has bought Illumina’s Infinium HD Human610-Quad BeadChips for the Generation R Study, which is backed in part by the Dutch government, industry partners, and the hospital.
Erasmus used Illumina’s HumanHap 550 BeadChip in a similar study of 10,000 individuals that was focused on late-age disease development, according to Andre Uitterlinden, from the hospital’s Internal Medicine department. The latest BeadChip will allow researchers to boost their throughput four times compared to the 550, he added.
Illumina said the 610-Quad, in addition to its extra 60,000 genetic markers, also includes proprietary CNV content the company developed through a collaboration with Decode Genetics.
Financial terms of the agreement were not released.